Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1462-000
Expected finish date:

Question

  1. What is the clinical effectiveness of octreotide long-acting release in combination with everolimus in patients with recurrent meningiomas?

Key Message

  • The systematic search resulted in 1 single-arm prospective study and 1 retrospective cohort study. No relevant randomized controlled trials, systematic reviews, or evidence-based guidelines were identified that met the criteria for this review.
  • Evidence was limited, inconsistent, and of low quality for the clinical effectiveness of octreotide long-acting release in combination with everolimus in patients with recurrent meningiomas.
  • The quantity and quality of current publications were not sufficient to draw a conclusion in support of or against the clinical effectiveness of octreotide long-acting release in combination with everolimus relative to other systematic therapies in patients with recurrent meningiomas.
  • Additional research is required to inform decision-making in this context.

Files

Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas View PDF
Last Updated : November 23, 2022